Disney vs Estée Lauder Stock, Which Is Best?
Inflation has eaten away at a lot of the money…
Sell
29
CC Quote, Financials, Valuation and Earnings
Last price:
$17.89
Seasonality move
:
8.87%
Day range:
$17.35 - $18.91
52-week range:
$15.10 - $32.48
Dividend yield:
5.33%
P/E ratio:
38.29x
P/S ratio:
0.49x
P/B ratio:
4.27x
Volume:
3.3M
Avg. volume:
1.7M
1-year change:
-40.03%
Market cap:
$2.8B
Revenue:
$6B
EPS (TTM):
$0.49
Analysts' Opinion
-
Consensus RatingThe Chemours has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.78, The Chemours has an estimated upside of 26.75% from its current price of $18.76.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $18.00 representing 4.05% downside risk from its current price of $18.76.
Fair Value
-
According to the consensus of 7 analysts, The Chemours has 26.75% upside to fair value with a price target of $23.78 per share.
CC vs. S&P 500
-
Over the past 5 trading days, The Chemours has overperformed the S&P 500 by 10.77% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
The Chemours does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
The Chemours has grown year-over-year revenues for 1 quarter straight. In the most recent quarter The Chemours reported revenues of $1.5B.
Earnings Growth
-
The Chemours earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter The Chemours reported earnings per share of -$0.18.
Enterprise value:
6.2B
EV / Invested capital:
--
Price / LTM sales:
0.49x
EV / EBIT:
20.23x
EV / Revenue:
1.09x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-9.26x
Price / Operating cash flow:
432.03x
Enterprise value / EBITDA:
10.31x
Gross Profit (TTM):
$1.1B
Return On Assets:
0.99%
Net Income Margin (TTM):
1.34%
Return On Equity:
10.59%
Return On Invested Capital:
1.63%
Operating Margin:
8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $7B | $6B | $5.8B | $1.5B | $1.5B | |
| Gross Profit | $1.8B | $1.3B | $1.1B | $273M | $286M | |
| Operating Income | $994M | -$130M | $373M | $57M | $120M | |
| EBITDA | $1.6B | $176M | $606M | $144M | $117M | |
| Diluted EPS | $5.60 | -$2.06 | $0.49 | $0.08 | -$0.18 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $2.6B | $3.4B | $3.5B | $3.7B | $3.1B | |
| Total Assets | $6.9B | $7.5B | $7.7B | $7.9B | $7.5B | |
| Current Liabilities | $1.3B | $1.8B | $2B | $2.2B | $1.8B | |
| Total Liabilities | $6.2B | $6.5B | $6.5B | $7.2B | $6.8B | |
| Total Equity | $734M | $999M | $1.3B | $757M | $659M | |
| Total Debt | $4.1B | $3.9B | $3.5B | $4B | $4B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $802M | $235M | -$289M | $131M | $139M | |
| Cash From Investing | $203M | -$164M | -$376M | $58M | -$75M | |
| Cash From Financing | -$690M | -$14M | -$126M | $324M | -$27M | |
| Free Cash Flow | $479M | -$67M | -$675M | $45M | $63M | |
CC
Sector
Market Cap
$2.8B
$18.7M
Price % of 52-Week High
57.76%
59.26%
Dividend Yield
5.33%
0%
Shareholder Yield
2.21%
1.61%
1-Year Price Total Return
-40.03%
-16.37%
Beta (5-Year)
1.828
1.053
Dividend yield:
5.33%
Annualized payout:
$1.00
Payout ratio:
193.51%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$17.14
200-day SMA
Sell
Level
$22.09
Bollinger Bands (100)
Sell
Level
17.77 - 20.45
Chaikin Money Flow
Buy
Level
74.8M
20-day SMA
Buy
Level
$18.13
Relative Strength Index (RSI14)
Buy
Level
53.84
ADX Line
Buy
Level
20.16
Williams %R
Sell
Level
-5.8252
50-day SMA
Sell
Level
$19.27
MACD (12, 26)
Sell
Level
-0.72
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
20.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.5593)
Sell
CA Score
(Annual)
Level (-1.9927)
Buy
Beneish M-Score
(Annual)
Level (-3.132)
Sell
Momentum Score
Level (3)
Sell
Ohlson Score
Level (0.3918)
Sell
Piotroski F Score
(Annual)
Level (3)
Buy
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
The Chemours Co is a global provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.
Stock Forecast FAQ
In the current month, CC has received 1 Buy ratings 6 Hold ratings, and 0 Sell ratings. The CC average analyst price target in the past 3 months is $23.78.
-
Where Will The Chemours Stock Be In 1 Year?
According to analysts, the consensus estimate is that The Chemours share price will rise to $23.78 per share over the next 12 months.
-
What Do Analysts Say About The Chemours?
Analysts are divided on their view about The Chemours share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Chemours is a Sell and believe this share price will drop from its current level to $18.00.
-
What Is The Chemours's Price Target?
The price target for The Chemours over the next 1-year time period is forecast to be $23.78 according to 7 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is CC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for The Chemours is a Hold. 6 of 7 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CC?
You can purchase shares of The Chemours via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Chemours shares.
-
What Is The The Chemours Share Price Today?
The Chemours was last trading at $17.89 per share. This represents the most recent stock quote for The Chemours. Yesterday, The Chemours closed at $18.76 per share.
-
How To Buy The Chemours Stock Online?
In order to purchase The Chemours stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SCHD a Good ETF to Buy?
With around $65.7 billion in net assets, Schwab’s US Dividend…
Is NAIL a Good ETF to Buy?
If you’re thinking about buying the NAIL ETF, this article…
Stock Ideas
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 40x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 117x
Sell
43
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 36x
Alerts
Buy
57
NARI alert for Jan 8
Inari Medical [NARI] is down 0.23% over the past day.
Buy
69
UNF alert for Jan 8
UniFirst [UNF] is up 4.97% over the past day.
Sell
31
APOG alert for Jan 8
Apogee Enterprises [APOG] is down 8.78% over the past day.
